Parexel International Corp (PRXL) Files Form 4 Insider Selling : Ulf I Schneider Sells 6,000 Shares

Parexel International Corp (PRXL): Ulf I Schneider , SVP & Chief Admin. Officer of Parexel International Corp sold 6,000 shares on May 23, 2016. The Insider selling transaction was reported by the company on May 24, 2016 to the Securities and Exchange Commission. The shares were sold at $60.01 per share for a total value of $360,060.00 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on May 24, 2016, Ulf I Schneider (SVP & Chief Admin. Officer) sold 6,000 shares at $60.01 per share price.On Mar 3, 2016, Christopher J Lindop (director) sold 2,000 shares at $60.28 per share price.Also, On Dec 2, 2015, Richard L Love (director) sold 1,330 shares at $68.21 per share price.On Nov 24, 2015, Eduard E. Holdener (director) sold 2,200 shares at $67.66 per share price.

PAREXEL International Corporation: On Friday, May 20, 2016 heightened volatility was witnessed in PAREXEL International Corporation which led to swings in the share price. The shares opened for trading at $58.81 and hit $59.75 on the upside , eventually ending the session at $59.51, with a gain of 1.76% or 1.03 points. The heightened volatility saw the trading volume jump to 3,58,033 shares. The 52-week high of the share price is $76.17 and the company has a market cap of $3,147,365 M . The 52-week low of the share price is at $56.

PAREXEL International Corporation Money Flow Index Chart

Company has been under the radar of several Street Analysts.PAREXEL International Corporation is Upgraded by Sun Trust Rbsn Humphrey to Buy. Earlier the firm had a rating of Neutral on the company shares. The Rating was issued on Mar 28, 2016.

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company which provides a range of expertise in clinical research clinical logistics medical communications consulting commercialization and advanced technology products and services to the pharmaceutical biotechnology and medical device industries across the world. The Company operates through three segments: Clinical Research Services PAREXEL Consulting Services and PAREXEL Informatics. Its product and service offerings include clinical trials management data management epidemiology health economics/outcomes research pharmacovigilance medical communications clinical pharmacology patient recruitment clinical supply and drug logistics post-marketing surveillance medical imaging services electronic data capture systems clinical trial management systems Web-based portals and other product development tools and services.

Leave a Reply

PAREXEL International Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on PAREXEL International Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.